The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity, an extension of market exclusivity for a drug, when specific pediatric studies are completed as requested. This extension is typically for six months.
When does pediatric exclusivity typically apply?
Pediatric exclusivity is granted when the FDA requests that a drug sponsor conduct clinical studies in the pediatric population for a specific drug [1]. Upon successful completion of these studies, the sponsor receives an additional six months of market exclusivity for that drug, running concurrently with any existing exclusivity periods [1]. This incentivizes research into the use of drugs in children.
How is pediatric exclusivity different from other exclusivity types?
Market exclusivity prevents generic or biosimilar manufacturers from entering the market with competing products. Different types of exclusivity exist, such as new chemical entity (NCE) exclusivity, orphan drug exclusivity, and pediatric exclusivity. Pediatric exclusivity is specifically tied to the completion of pediatric studies as mandated by the FDA, whereas other exclusivities may be based on the drug's approval as a new drug, its use in rare diseases, or other criteria [1]. The duration and conditions for each type of exclusivity vary.
How long does pediatric exclusivity last?
Pediatric exclusivity typically adds six months to the existing exclusivity period of a drug [1]. This extension begins once the existing exclusivity period has expired or is about to expire, and it runs concurrently with other exclusivity periods.
What are the requirements for obtaining pediatric exclusivity?
To obtain pediatric exclusivity, a drug sponsor must agree to conduct, and then successfully complete, pediatric clinical trials as requested by the FDA [1]. These studies are designed to gather data on the drug's safety and efficacy in children. The FDA may request these studies before approval or after approval as a post-marketing requirement.
Where can I find a list of drugs with pediatric exclusivity?
Information regarding pediatric exclusivity, including granted extensions and pending requests, can often be found through regulatory filings and databases. DrugPatentWatch.com provides a resource for tracking patent and exclusivity information for pharmaceutical products [2]. While a specific "complete list" for 2024 may not be publicly aggregated in a single document by the FDA, resources like DrugPatentWatch compile such data based on regulatory approvals and filings [2].
What is the impact of pediatric exclusivity on drug availability?
Pediatric exclusivity delays the entry of generic or biosimilar competitors into the market. This means that the branded drug remains the sole option for patients for the duration of the exclusivity period, potentially impacting drug pricing and patient access to more affordable alternatives [1].
How does pediatric exclusivity affect drug development?
The prospect of pediatric exclusivity encourages pharmaceutical companies to invest in pediatric research, which has historically been understudied compared to adult populations [1]. By incentivizing these studies, the FDA aims to ensure that children have access to safe and effective treatments tailored to their needs.
Can pediatric exclusivity be challenged?
Like other forms of market exclusivity, pediatric exclusivity can be subject to legal challenges. Competitors, such as generic drug manufacturers, may challenge the validity or duration of exclusivity periods if they believe the requirements have not been met or that the exclusivity is being unfairly maintained.
What are the potential benefits of pediatric exclusivity for children's health?
The primary benefit of pediatric exclusivity is the generation of crucial data on how drugs affect children. This research can lead to improved dosing, better understanding of side effects in pediatric populations, and the development of new formulations or treatments specifically for children [1].
What are the financial implications of pediatric exclusivity?
For pharmaceutical companies, pediatric exclusivity extends the period of market exclusivity, allowing them to maintain higher prices and recoup their research and development investments for a longer duration. For patients and healthcare systems, it can mean continued higher costs for medications until generic or biosimilar alternatives become available [1].
How does the FDA decide to request pediatric studies?
The FDA decides to request pediatric studies based on several factors, including whether the drug is intended for use in a pediatric population, whether existing data suggests the drug may be safer or more effective in children, or if there are known safety concerns in children that require further investigation [1]. The request is made to ensure that adequate information is available to treat pediatric patients.
Sources:
[1] https://www.fda.gov/about-fda/pediatric-drug-development/pediatric-exclusivity
[2] https://www.drugpatentwatch.com/